IDH2 Gene Mutation clinical trials at UCSF
2 in progress, 1 open to eligible people
The IDH2 gene mutation changes how cells grow and divide. UCSF is conducting trials to test the effects of BGB-290 and temozolomide on brain tumors with this mutation. The study aims to identify the safest and most effective doses for young and adult patients.
BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas
open to eligible people ages 13-25
This phase I trial studies the side effects and best dose of BGB-290 and temozolomide in treating adolescents and young adults with IDH1/2-mutant grade I-IV glioma that is newly diagnosed or has come back. BGB-290 may stop the growth of tumor cells…
San Francisco, California and other locations
Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)
Sorry, in progress, not accepting new patients
Study AG881-C-004 is a phase 3, multicenter, randomized, double-blind, placebo-controlled study comparing the efficacy of vorasidenib to placebo in participants with residual or recurrent Grade 2 glioma with an IDH1 or IDH2 mutation who have…
San Francisco, California and other locations
Our lead scientists for IDH2 Gene Mutation research studies include Sabine Mueller.
Last updated: